The House Ways and Means Trade Subcommittee recently held a hearing on U.S.-India trade relations during which industry groups reportedly called on Congress to pressure India to reform purportedly protectionist policies that have, among other matters, damaged drug patent rights in favor of Indian generic companies and allegedly abused compulsory drug licenses for the benefit of domestic firms. U.S. government officials are considering the renewal of U.S. trade benefits for India under the Generalized System of Preferences program, which expires July 31, 2013. India is apparently one of the largest recipients of benefits under the program; in 2011, it exported $3.7 billion in goods to the United States, or one-tenth of its total exports to this country, as part of the program. Some of those testifying during the March 13, 2013, hearing were reluctant to curtail India’s involvement in the program, because that would not likely change its protectionist behavior and could instead be viewed as trade retaliation. The better course, they suggested, would be to challenge India’s drug, technology and farm policies before the World Trade Organization. See Committee on Ways and Means Hearing Advisory, March 6, 2013; Reuters, March 13, 2013.